Latest Cancer Cure News 2023

Latest Cancer Cure News 2023 

The approval of CAR T cell therapy marked the beginning of a revolutionary era in cancer treatment.

Over the past five years, following the FDA's initial endorsement of chimeric antigen receptor (CAR) T cell therapy, the University of Pennsylvania's Penn Medicine has secured an additional 20 approvals related to drugs and methodologies for detecting or treating cancer.

Rather than being a singular disease category, the term "cancer" encompasses over 100 distinct diseases that share the commonality of originating from rapidly dividing cells. Given the diversity in cancer types and their corresponding treatment requirements, the surge of new therapies emerging from various institutions is reflective of the evolving landscape of cancer treatment.

Win Lottery
Get Chance to Win Lottery


What accounts for this profusion of advancements in just half a decade?

According to Dr. Robert Vonderheide, Director of the Abramson Cancer Center (ACC), this influx of new cancer therapies can be attributed to a recent explosion in our understanding of cancer biology.

This surge of knowledge predominantly pertains to the immune system's capacity to combat cancer, a concept that was met with skepticism until about two decades ago. With the clinical validation of the immune system's efficacy against cancer, a floodgate of ideas on ways to exploit this vulnerability was opened. Dr. Vonderheide explains, "As soon as we had clinical validation for this Achilles heel in cancer, the dam burst for ideas about other ways to exploit that vulnerability to come forward. The first drug that came out to activate the immune system inspired the rest of the field to find the next drug, and the one after that. We as a field have moved from serendipity and empiricism to science-driven drug design."

The initial approval of CAR T cell therapy motivated Penn faculty members to explore novel methods of leveraging the immune system in cancer treatment.

Such approvals provide a tangible dimension to the work researchers are engaged in. Dr. Avery Posey, whose lab team at the Perelman School of Medicine is focused on identifying specific antigens for solid tumors and optimizing engineered donor T cells, underscores the motivating impact of these approvals: "It brings a new perspective, showing that your work is more than basic research and can actually become drugs that impact patients' lives. That's a real motivator to keep pushing forward."

Notably, the quest for innovative immunotherapies is only one facet of Penn's cancer research. Many recently approved cancer treatments or detection techniques developed at the institution don't solely rely on immune system engagement. Penn researchers have been exploring a range of approaches to enhance cancer patient care.

For instance, there's olaparib, also known as Lynparza, used to treat ovarian and breast cancers linked to BRCA gene mutations. By targeting the PARP enzyme responsible for cell repair, olaparib halts the growth of cancer cells. Pafolacianine (Cytalux), approved as the first agent to illuminate cancer lesions during surgery, enabling precise tumor removal, and belzutifan (Welireg), a groundbreaking treatment for von Hippel-Lindau disease-associated tumors.

The progress in cancer treatment has contributed to a significant decrease in cancer-related mortality in the United States, dropping by 33% since 1991. Dr. Vonderheide emphasizes that every drug advertised on television, once unknown, was initially tested in clinical trials with patients. This transformation is the driving force behind the commitment of medical professionals and researchers in the field.

Moreover, the success of high-risk, high-reward trials in cancer clinical research has prompted many innovations to gain traction quickly.

While cancer treatments might be initially designed to address cancer, their broader applications often emerge over time. CAR T cell therapy, for instance, is demonstrating potential beyond cancer, including autoimmune diseases like lupus.

Dr. Emma Meagher, Senior Vice Dean for Clinical and Translational Research, points out that CAR T cell therapy's applicability to other diseases is gaining momentum. The therapy's translation to autoimmune, neurological, rheumatological, and dermatological conditions indicates its potential in areas beyond oncology. Penn is positioned to play a significant role in this expanding field.

Penn Medicine's relentless pursuit of medical advancements has led to a host of FDA approvals, transforming the landscape of cancer treatment. This journey from innovation to implementation is facilitated by Penn's robust infrastructure, enabling efficient progression from concept to approval. Ultimately, these advancements place life-changing treatments and vaccines within reach, shaping the future of medical care.

Comments

Popular posts from this blog

Python map() function with Examples

Canada wildfire: all 20000 Yellowknife residents evacuating

Ebook Download Free Roman and Sharon

Split() String method in Java with examples

7 Top Sorting Algorithms in Data Structure